Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company’s active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company provides menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
Metrics to compare | NECT | Peers Peers - average of corresponding metrics from companies closely matching NECT: MOREPENLAB, CIPLA, GRANULES, GLENMARK, 506919 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNECTPeersSector |
---|---|---|---|---|
P/E Ratio | 145.5x | 28.0x | −0.6x | |
PEG Ratio | 1.18 | 0.55 | 0.00 | |
Price/Book | 0.8x | 4.5x | 2.6x | |
Price / LTM Sales | 0.5x | 3.3x | 3.2x | |
Upside (Analyst Target) | - | 3.6% | 46.5% | |
Fair Value Upside | Unlock | −13.0% | 6.6% | Unlock |